ArticlePloS one2024
Impact of urinary PAHs on psoriasis risk in U.S. adults: Insights from NHANES.
Article in PloS one, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveExposure to environmental pollutants is increasingly recognized as a risk factor for the development of psoriasis. Polycyclic aromatic hydrocarbons (PAHs) are ubiquitous in the air and might induce reactions such as oxidative stress. Nevertheless, it is still unclear if PAHs have any influence on the prevalence of psoriasis over the entire population of the United States. The objective of this study was to assess the association between urine PAHs and psoriasis.
methodsThe research included 3,673 individuals aged 20 years or older who participated in the 2003-2006 and 2009-2012 National Health and Nutrition Examination Surveys (NHANES). We employed logistic regression models to evaluate the relationship between levels of urine PAH metabolites and psoriasis and smoothed curve fitting to illustrate the concentration-response relationship. Additionally, subgroup and interaction analyses were conducted to elucidate these associations. Furthermore, we employed weighted quartile sum (WQS) regressions to examine the distinct effects of individual and mixed urine PAH metabolites on psoriasis. However, it is important to note that the NHANES sample may be subject to selectivity and self-reporting bias, which may influence the data' generalisability.
resultsWe observed that the highest tertiles of 2-NAP and 2-FLU had a 63% (95% CI 1.02, 2.61) and 83% (95% CI 1.14, 2.96) higher odds of association with psoriasis prevalence, respectively. Meanwhile, tertile 2 and tertile 3 of 3-PHE were also significantly associated with psoriasis, with higher odds of 65% (95% CI 1.01, 2.69) and 14% (95% CI 1.17, 3.00), respectively. The subgroup analyses revealed a significant correlation between urine PAH metabolites and the odds of psoriasis in specific groups, including males, aged 40-60 years, with a BMI > 30, and those with hyperlipidemia. In the WQS model, a positive association was found between the combination of urine PAH metabolites and psoriasis (OR 1.43, 95% CI 1.11, 1.84), with 2-FLU being the most prevalent component across all mixtures (0.297).
conclusionsOur findings indicate a significant association between urine PAH metabolites and the odds of psoriasis prevalence in adults. Among these metabolites, 2-FLU demonstrated the most prominent impact. Controlling PAH exposure, as an important strategy for minimizing exposure to environmental contaminants and lowering the risk of psoriasis, is critical for raising public knowledge about environmental health and preserving public health.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.